HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon refinances

This article was originally published in The Rose Sheet

Executive Summary

Revlon will refinance and replace its existing $800 mil. term loan with a new five-year $840 mil. term loan, company announces Nov. 29. The move supports the firm's previously announced plans to improve cash flow and strengthen its balance sheet. Revlon also will amend its existing $160 mil. revolving credit facility and extend its maturity through the same five-year period. The firm expects its financial decisions to result in lower interest margins, which will lead to annual interest savings, greater financial flexibility and longer maturity dates for existing bank credit agreements, Revlon says. The credit facilities are expected to close by the end of the month. The company is currently $800 mil. in debt; CEO David Kennedy announced his reorganization strategy in November (1"The Rose Sheet" Nov. 13, 2006, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel